glp-1 agonists and anesthesia risk: Assessment of gastric content using ultrasound New therapeutic agents for type
Description
All bases covered

They have come into the limelight after a large double-blinded study published in NEJM, showed an average 14.9% dec

Here, the authors examine the biological effects of incretins and other metabolic hormones, such as glucagon and amylin, as well as discussing current clinical data demonstrating the organ-protective effects of incretin drugs and their potential underlying mechanisms.

Additionally, this paper explores the potential applications of GLP-1 receptor agonists (GLP-1RAs) in fields such as neuroprotection, anti-infection measures, the reduction of various types of inflammation, and the enhancement of cardiovascular function
This article examines clinical evidence for combination therapy, safety profiles, and how genetic predispositions in GLP-1 and glucose metabolism pathways may info

Their potential for disease modification and symptom relief, particularly in specific phenotypes, supports their further exploration as part of a personalized treatment approach.